ATE324877T1 - Behandlung von metastatischer krankheit - Google Patents
Behandlung von metastatischer krankheitInfo
- Publication number
- ATE324877T1 ATE324877T1 AT00955687T AT00955687T ATE324877T1 AT E324877 T1 ATE324877 T1 AT E324877T1 AT 00955687 T AT00955687 T AT 00955687T AT 00955687 T AT00955687 T AT 00955687T AT E324877 T1 ATE324877 T1 AT E324877T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- metastatic disease
- compounds
- metastatic
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14925899P | 1999-08-17 | 1999-08-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE324877T1 true ATE324877T1 (de) | 2006-06-15 |
Family
ID=22529456
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00955687T ATE324877T1 (de) | 1999-08-17 | 2000-08-17 | Behandlung von metastatischer krankheit |
Country Status (10)
Country | Link |
---|---|
EP (2) | EP1242060B1 (de) |
JP (2) | JP2003516930A (de) |
AT (1) | ATE324877T1 (de) |
AU (1) | AU6784400A (de) |
CA (1) | CA2380888A1 (de) |
DE (1) | DE60027768T2 (de) |
DK (1) | DK1242060T3 (de) |
ES (1) | ES2261230T3 (de) |
PT (1) | PT1242060E (de) |
WO (1) | WO2001012172A1 (de) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7192698B1 (en) | 1999-08-17 | 2007-03-20 | Purdue Research Foundation | EphA2 as a diagnostic target for metastatic cancer |
US6927203B1 (en) | 1999-08-17 | 2005-08-09 | Purdue Research Foundation | Treatment of metastatic disease |
CZ304942B6 (cs) | 2000-03-31 | 2015-02-04 | Purdue Research Foundation | Léčivo pro zvyšování specifické eliminace populace tumorových buněk a farmaceutický prostředek obsahující konjugát fosfát-FITC nebo fosfát-dinitrofenyl |
US7101976B1 (en) | 2000-09-12 | 2006-09-05 | Purdue Research Foundation | EphA2 monoclonal antibodies and methods of making and using same |
CA2369183A1 (en) * | 2001-01-23 | 2002-07-23 | Amsterdam Support Diagnostics B.V. | Means and methods for treatment evaluation |
EP1225233A3 (de) * | 2001-01-23 | 2003-01-08 | Amsterdam Support Diagnostics B.V. | Mittel und Methoden für die Abschätzung einer Behandlung |
EP1298221A1 (de) * | 2001-09-28 | 2003-04-02 | PrimaGen Holding B.V. | Mittel und Methoden für die Abschätzung einer Behandlung |
CA2461877A1 (en) * | 2001-09-28 | 2003-04-10 | Purdue Research Foundation | Method of treatment using ligand-immunogen conjugates |
EP1474535A4 (de) * | 2002-02-15 | 2006-11-08 | Millennium Pharm Inc | Verfahren und zusammensetzungen zur behandlung von mit aids und hiv in zusammenhang stehenden erkrankungen unter verwendung der moleküle 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784 oder 2045 |
CA2485373A1 (en) * | 2002-05-10 | 2003-11-20 | Medimmune, Inc. | Epha2 monoclonal antibodies and methods of use thereof |
US20040091486A1 (en) * | 2002-05-10 | 2004-05-13 | Kinch Michael S. | EphA2 agonistic monoclonal antibodies and methods of use thereof |
WO2005051307A2 (en) * | 2003-11-20 | 2005-06-09 | Medimmune, Inc. | Epha2 agonistic monoclonal antibodies and methods of use thereof |
CA2486615A1 (en) | 2002-05-23 | 2003-12-04 | Purdue Research Foundation | Low molecular weight protein tyrosine phosphatase (lmw-ptp) as a diagnostic and therapeutic target |
AU2004210463B2 (en) * | 2003-02-07 | 2009-07-16 | Ludwig Institute For Cancer Research Limited | Eph/ephrin mediated modulation of cell adhesion and tumour cell metastasis |
AU2003900541A0 (en) * | 2003-02-07 | 2003-02-20 | Ludwig Institute For Cancer Research | Modulation of cell adhesion and tumour cell metastasis |
JP2006523240A (ja) * | 2003-04-11 | 2006-10-12 | メディミューン,インコーポレーテッド | EphA2、低増殖性細胞障害ならびに上皮および内皮の再構成 |
WO2004091375A2 (en) * | 2003-04-11 | 2004-10-28 | Medimmune, Inc. | Epha2 and non-neoplastic hyperproliferative cell disorders |
EP1628992A4 (de) | 2003-05-13 | 2008-04-16 | Novartis Vaccines & Diagnostic | Verfahren zur modulation der metastasierung sowie von metastasen herrührender verwandter ereignisse im skelett |
WO2005016381A2 (en) * | 2003-07-21 | 2005-02-24 | Medimmune, Inc. | Combination therapy for the treatment and prevention of cancer using epha2, pcdgf, and haah |
ATE420965T1 (de) | 2004-05-18 | 2009-01-15 | Alphavax Inc | Von tc-83 abgeleitete alphavirus-vektoren, partikel und verfahren |
CA2577370A1 (en) | 2004-08-16 | 2006-03-02 | Medimmune, Inc. | Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity |
WO2006084226A2 (en) | 2005-02-04 | 2006-08-10 | Raven Biotechnologies, Inc. | Antibodies that bind to epha2 and methods of use thereof |
WO2007092299A2 (en) | 2006-02-03 | 2007-08-16 | Purdue Research Foundation | Targeted conjugates and radiation |
ES2673822T3 (es) * | 2006-07-18 | 2018-06-25 | Sanofi | Anticuerpo antagonista contra EphA2 para el tratamiento de cáncer |
WO2008033966A2 (en) | 2006-09-12 | 2008-03-20 | Alphavax, Inc. | Alphavirus replicon particles matched to protein antigens as immunological adjuvants |
EP2066346B1 (de) | 2006-09-12 | 2019-07-03 | AlphaVax, Inc. | Für il-12 kodierende alphavirusreplikationspartikel als immunologische hilfsstoffe |
DK2099485T3 (en) | 2006-11-03 | 2018-05-22 | Alphavax Inc | Alphavirus and alphavirus replica particle formulations and associated methods |
TWI443109B (zh) | 2007-08-30 | 2014-07-01 | Daiichi Sankyo Co Ltd | 抗epha2抗體 |
TW201116297A (en) | 2009-10-02 | 2011-05-16 | Sanofi Aventis | Antibodies that specifically bind to the EphA2 receptor |
JP5875054B2 (ja) * | 2013-02-13 | 2016-03-02 | 国立大学法人 東京大学 | がんの検査方法及び検査用キット |
WO2018034332A1 (ja) * | 2016-08-19 | 2018-02-22 | 国立大学法人東京大学 | EphA2 N末端フラグメント抗体 |
US20210268098A1 (en) | 2018-08-03 | 2021-09-02 | Uab Research Foundation | Methods and compositions for alphavirus vaccine |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0656367A1 (de) | 1991-08-22 | 1995-06-07 | Becton, Dickinson and Company | Methoden und Zusammensetzungen zur Krebstherapie und zur Vorhersagbarkeit der Reaktionen auf diese Behandlung |
CA2103323A1 (en) * | 1992-11-24 | 1994-05-25 | Gregory D. Plowman | Her4 human receptor tyrosine kinase |
US5811098A (en) | 1992-11-24 | 1998-09-22 | Bristol-Myers Squibb Company | Antibodies to HER4, human receptor tyrosine kinase |
US5587459A (en) | 1994-08-19 | 1996-12-24 | Regents Of The University Of Minnesota | Immunoconjugates comprising tyrosine kinase inhibitors |
ATE293989T1 (de) * | 1998-11-20 | 2005-05-15 | Genentech Inc | Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten |
-
2000
- 2000-08-17 PT PT00955687T patent/PT1242060E/pt unknown
- 2000-08-17 AU AU67844/00A patent/AU6784400A/en not_active Abandoned
- 2000-08-17 JP JP2001516518A patent/JP2003516930A/ja active Pending
- 2000-08-17 CA CA002380888A patent/CA2380888A1/en not_active Abandoned
- 2000-08-17 DK DK00955687T patent/DK1242060T3/da active
- 2000-08-17 EP EP00955687A patent/EP1242060B1/de not_active Revoked
- 2000-08-17 AT AT00955687T patent/ATE324877T1/de not_active IP Right Cessation
- 2000-08-17 WO PCT/US2000/022670 patent/WO2001012172A1/en active IP Right Grant
- 2000-08-17 EP EP10010861A patent/EP2289940A3/de not_active Withdrawn
- 2000-08-17 ES ES00955687T patent/ES2261230T3/es not_active Expired - Lifetime
- 2000-08-17 DE DE60027768T patent/DE60027768T2/de not_active Revoked
-
2007
- 2007-08-15 JP JP2007211840A patent/JP2007306938A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU6784400A (en) | 2001-03-13 |
DE60027768D1 (de) | 2006-06-08 |
EP2289940A3 (de) | 2011-09-21 |
CA2380888A1 (en) | 2001-02-22 |
EP1242060B1 (de) | 2006-05-03 |
JP2003516930A (ja) | 2003-05-20 |
EP2289940A2 (de) | 2011-03-02 |
WO2001012172B1 (en) | 2001-08-16 |
EP1242060A4 (de) | 2003-09-24 |
WO2001012172A1 (en) | 2001-02-22 |
JP2007306938A (ja) | 2007-11-29 |
DK1242060T3 (da) | 2006-08-21 |
EP1242060A1 (de) | 2002-09-25 |
DE60027768T2 (de) | 2007-04-05 |
PT1242060E (pt) | 2006-08-31 |
ES2261230T3 (es) | 2006-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE324877T1 (de) | Behandlung von metastatischer krankheit | |
GB9903762D0 (en) | Organic compounds | |
TR200003514T2 (tr) | Pirol ikame edilmiş 2-indolinon protein kinaz inhibitörleri | |
BR0108396A (pt) | Derivados de pirimidina-4-0na como inibidores de ldl-pla(2) | |
CA2366932A1 (en) | Cyclic protein tyrosine kinase inhibitors | |
DE60113733D1 (de) | Verwendung von cyclopamine, zur behandlung des basalzellkarzinoms und anderer tumoren | |
ATE305788T1 (de) | (s,s)-reboxetin zur behandlung von inkontinenz | |
WO2005030121A3 (en) | Compounds, compositions and methods | |
DE502004002571D1 (de) | Substituierte 3-pyrrolidin-indol-derivate | |
NO2010002I2 (no) | Toceranibfosfat. | |
BR0215360A (pt) | Derivados de indolina úteis como inibidores de proteìna quinase | |
MY141144A (en) | 1, 5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-dipyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases | |
CA2367704A1 (en) | Pyrazolobenzodiazepines as cdk2 inhibitors | |
BR0209149A (pt) | Ftalazinonas | |
EA200600424A1 (ru) | Применение полипептидов семейства купредоксинов при лечении рака | |
EA200800011A1 (ru) | Тиенопиримидиновые и тиенопиридиновые модуляторы киназы | |
TR200200260T2 (tr) | N-desmetilzopiklonlarının üretim ve kullanım yöntemleri | |
TR200401316T4 (tr) | Proliferatif hastalıkları tedavi etmek için yöntemler ve bileşikler | |
DE60033918D1 (de) | Polysubstituted 6-phenylphenanthridines mit pde-iv hemmender wirkung | |
ATE311389T1 (de) | Wirkstoffvorläufer von imidazopyridin-derivaten | |
DE60019894D1 (de) | Phenantrhridin-n-oxides mit pde-iv hemmender wirkung | |
DE60106409D1 (de) | 3-aminopyrazole als inhibitoren von cyclinabhängigen kinasen | |
DE60011794D1 (de) | Verwendung von docetaxel für die behandlung von hepatozelluläre krebs | |
ATE411036T1 (de) | Verwendung von aplidine in der behandlung von pankreaskrebs | |
ATE420636T1 (de) | Hemmer der protonenabhängigen kationenkanäle und deren verwendung in der behandlung von ischemiebedingten erkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1242060 Country of ref document: EP |
|
RZN | Patent revoked |